The past six decades have seen remarkable improvements in health outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young children. However, although life expectancy for people with cystic fibrosis has increased substantially, the disease continues to limit survival and quality of life, and results in a large burden of care for people with cystic fibrosis and their families. Furthermore, epidemiological studies in the past two decades have shown that cystic fibrosis occurs and is more frequent than was previously thought in populations of non-European descent, and the disease is now recognised in many regions of the world. The Lancet Respiratory Medicine Commission on the future of cystic fibrosis care was established at a time of great change in the clinical care of people with the disease, with a growing population of adult patients, widespread genetic testing supporting the diagnosis of cystic fibrosis, and the development of therapies targeting defects in the cystic fibrosis transmembrane conductance regulator (CFTR), which are likely to affect the natural trajectory of the disease. The aim of the Commission was to bring to the attention of patients, health-care professionals, researchers, funders, service providers, and policy makers the various challenges associated with the changing landscape of cystic fibrosis care and the opportunities available for progress, providing a blueprint for the future of cystic fibrosis care. The discovery of the CFTR gene in the late 1980s triggered a surge of basic research that enhanced understanding of the pathophysiology and the genotype-phenotype relationships of this clinically variable disease. Until recently, available treatments could only control symptoms and restrict the complications of cystic fibrosis, but advances in CFTR modulator therapies to address the basic defect of cystic fibrosis have been remarkable and the field is evolving rapidly. However, CFTR modulators approved for use to date are highly expensive, which has prompted questions about the affordability of new treatments and served to emphasise the considerable gap in health outcomes for patients with cystic fibrosis between high-income countries, and low-income and middle-income countries (LMICs). Advances in clinical care have been multifaceted and include earlier diagnosis through the implementation of newborn screening programmes, formalised airway clearance therapy, and reduced malnutrition through the use of effective pancreatic enzyme replacement and a high-energy, high-protein diet. Centre-based care has become the norm in high-income countries, allowing patients to benefit from the skills of expert members of multidisciplinary teams. Pharmacological interventions to address respiratory manifestations now include drugs that target airway mucus and airway surface liquid hydration, and antimicrobial therapies such as antibiotic eradication treatment in early-stage infections and protocols for maintenance therapy of chronic infections. Despite the recent breakthrough with CFTR modulators for cystic fibrosis, the development of novel mucolytic, anti-inflammatory, and anti-infective therapies is likely to remain important, especially for patients with more advanced stages of lung disease. As the median age of patients with cystic fibrosis increases, with a rapid increase in the population of adults living with the disease, complications of cystic fibrosis are becoming increasingly common. Steps need to be taken to ensure that enough highly qualified professionals are present in cystic fibrosis centres to meet the needs of ageing patients, and new technologies need to be adopted to support communication between patients and health-care providers. In considering the future of cystic fibrosis care, the Commission focused on five key areas, which are discussed in this report: the changing epidemiology of cystic fibrosis (section 1); future challenges of clinical care and its delivery (section 2); the building of cystic fibrosis care globally (section 3); novel therapeutics (section 4); and patient engagement (section 5). In panel 1, we summarise key messages of the Commission. The challenges faced by all stakeholders in building and developing cystic fibrosis care globally are substantial, but many opportunities exist for improved care and health outcomes for patients in countries with established cystic fibrosis care programmes, and in LMICs where integrated multidisciplinary care is not available and resources are lacking at present. A concerted effort is needed to ensure that all patients with cystic fibrosis have access to high-quality health care in the future.

Alder Hey Children's Hospital Liverpool UK; University of Liverpool Liverpool UK

Charité Universitätsmedizin Berlin Berlin Institute of Health Berlin Germany; German Center for Lung Research Berlin Germany

CS Mott Children's Hospital Ann Arbor MI USA; University of Michigan Ann Arbor MI USA

Cystic Fibrosis Centre IRCCS Istituto Giannina Gaslini Genoa Italy

Cystic Fibrosis Centre University Hospital Leuven Leuven Belgium

Cystic Fibrosis Clinic British Columbia Children's Hospital Vancouver BC Canada

Cystic Fibrosis Trust London UK

Department of Biology and Medical Genetics 2nd Faculty of Medicine Motol University Hospital Charles University Prague Czech Republic

Department of Medical Microbiology 2nd Faculty of Medicine Motol University Hospital Charles University Prague Czech Republic

Department of Thoracic Medicine The Prince Charles Hospital Brisbane QLD Australia; QIMR Berghofer Medical Research Institute Brisbane QLD Australia

Division of Paediatric Pulmonology and MRC Unit for Child and Adolescent Health University of Cape Town Cape Town South Africa; Red Cross War Memorial Children's Hospital Cape Town South Africa

European Medicines Agency Amsterdam Netherlands

Hadassah Medical Centre Jerusalem Israel

Hôpital Cochin Assistance Publique Hôpitaux de Paris Paris France; Université Paris Descartes Institut Cochin Paris France

Hospital de Pediatria Juan P Garrahan Buenos Aires Argentina

Jessa Ziekenhuis Holsbeek Belgium

Johns Hopkins University Baltimore MD USA

Lee Kong Chian School of Medicine Nanyang Technological University Singapore

Post Graduate Institute of Medical Education and Research Chandigarh India

Queen's University of Belfast Belfast UK

Research Center for Medical Genetics Moscow Russia

Royal Brompton and Harefield NHS Foundation Trust London UK

Royal Brompton and Harefield NHS Foundation Trust London UK; National Heart and Lung Institute Imperial College London UK

Royal Prince Alfred Hospital Sydney NSW Australia; Woolcock Institute of Medical Research Sydney NSW Australia

School of Medicine St Vincent's University Hospital Dublin Ireland; University College Dublin School of Medicine Dublin Ireland

St Michael's Hospital Toronto ON Canada; University of Toronto Toronto ON Canada

Starship Children's Hospital Auckland New Zealand; University of Auckland Auckland New Zealand

Universities of Giessen and Marburg Lung Center German Center of Lung Research Justus Liebig University Giessen Giessen Germany

University of Alabama at Birmingham Birmingham AL USA

University of Toronto Toronto ON Canada; Division of Respiratory Medicine Department of Paediatrics Translational Medicine Research Program The Hospital for Sick Children University of Toronto Toronto ON Canada

University of Washington Seattle WA USA

University of Washington Seattle WA USA; Seattle Children's Research Institute Seattle WA USA

University of Wisconsin Madison WI USA

Komentář v

Lancet Respir Med. 2020 Jan;8(1):12-14. doi: 10.1016/S2213-2600(19)30335-2. PubMed

Komentář v

Lancet Respir Med. 2020 Jan;8(1):14-16. doi: 10.1016/S2213-2600(19)30336-4. PubMed

Komentář v

Lancet Respir Med. 2020 Jan;8(1):8-10. doi: 10.1016/S2213-2600(19)30333-9. PubMed

Komentář v

Lancet Respir Med. 2020 Jan;8(1):10-12. doi: 10.1016/S2213-2600(19)30334-0. PubMed

Erratum v

Lancet Respir Med. 2019 Dec;7(12):e40. doi: 10.1016/S2213-2600(19)30408-4. PubMed

Komentář v

Lancet Respir Med. 2020 Apr;8(4):e17. doi: 10.1016/S2213-2600(20)30055-2. PubMed

Zobrazit více v PubMed

Andersen DH, Hodges RG. Celiac syndrome; genetics of cystic fibrosis of the pancreas, with a consideration of etiology. Am J Dis Child 1946; 72: 62–80. PubMed

Di Sant’Agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics 1953; 12(5): 549–63. PubMed

Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23(3): 545–9. PubMed

Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983; 301(5899): 421–2. PubMed

Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245(4922): 1073–80. PubMed

Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245(4922): 1066–73. PubMed

Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245(4922): 1059–65. PubMed

Gentzsch M, Mall MA. Ion Channel Modulators in Cystic Fibrosis. Chest 2018; 154(2): 383–93. PubMed PMC

http://www.genet.sickkids.on.ca/

http://www.cftr2.org/.

Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013; 1(2): 158–63. PubMed

de Souza DAS, Faucz FR, Pereira-Ferrari L, Sotomaior VS, Raskin S. Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling. Andrology 2018; 6(1): 127–35. PubMed PMC

Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 2010; 1214: 57–69. PubMed PMC

Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers 2015; 1: 15010. PubMed PMC

Elborn JS. Cystic fibrosis. Lancet 2016; 388(10059): 2519–31. PubMed

Stephenson AL, Stanojevic S, Sykes J, Burgel PR. The changing epidemiology and demography of cystic fibrosis. Presse Med 2017; 46(6 Pt 2): e87–e95. PubMed

Burgel PR, Bellis G, Olesen HV, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 2015; 46(1): 133–41. PubMed

Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 2013; 1(2): 164–74. PubMed

Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 2015; 145: 19–34. PubMed

De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med 2016; 4(8): 662–74. PubMed

Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365(18): 1663–72. PubMed PMC

Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187(11): 1219–25. PubMed PMC

Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 2015; 373(3): 220–31. PubMed PMC

Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2017; 5(7): 557–67. PubMed

Simmonds NJ. Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis. Paediatr Respir Rev 2019. PubMed

Kharrazi M, Yang J, Bishop T, et al. Newborn Screening for Cystic Fibrosis in California. Pediatrics 2015; 136(6): 1062–72. PubMed

Mishra A, Greaves R, Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era. Clin Biochem Rev 2005; 26(4): 135–53. PubMed PMC

Kabra SK, Kabra M, Shastri S, Lodha R. Diagnosing and managing cystic fibrosis in the developing world. Paediatr Respir Rev 2006; 7 Suppl 1: S147–50. PubMed

Ferec C, Cutting GR. Assessing the Disease-Liability of Mutations in CFTR. Cold Spring Harb Perspect Med 2012; 2(12): a009480. PubMed PMC

Marson FAL, Bertuzzo CS, Ribeiro JD. Classification of CFTR mutation classes. Lancet Respir Med 2016; 4(8): e37–e8. PubMed

Amaral MD, Balch WE. Hallmarks of therapeutic management of the cystic fibrosis functional landscape. J Cyst Fibros 2015; 14(6): 687–99. PubMed PMC

Martiniano SL, Sagel SD, Zemanick ET. Cystic fibrosis: a model system for precision medicine. Curr Opin Pediatr 2016; 28(3): 312–7. PubMed PMC

Wilson JMG JG. Principles and practice of screening for disease. Geneva: WHO. http://wwwwhoint/bulletin/volumes/86/4/07-050112BPpdf 1968. PubMed

Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001; 107(1): 1–13. PubMed

Gonska T, Ratjen F. Newborn screening for cystic fibrosis. Expert Rev Respir Med 2015; 9(5): 619–31. PubMed

Coffey MJ, Whitaker V, Gentin N, et al. Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era. J Pediatr 2017; 181: 137–45 e1. PubMed

Tridello G, Castellani C, Meneghelli I, Tamanini A, Assael BM. Early diagnosis from newborn screening maximises survival in severe cystic fibrosis. ERJ Open Res 2018; 4(2). PubMed PMC

Hayeems RZ, Miller FA, Barg CJ, et al. Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis. J Pediatr 2017; 184: 165–71 e1. PubMed

Schmidt M, Werbrouck A, Verhaeghe N, et al. Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations. J Cyst Fibros 2018; 17(3): 306–15. PubMed

Sommerburg O, Stahl M, Hammermann J, et al. [Newborn Screening on Cystic Fibrosis in Germany: Comparison of the new Screening Protocol with an Alternative Protocol]. Klin Padiatr 2017; 229(2): 59–66. PubMed

Ren CL, Borowitz DS, Gonska T, et al. Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis. J Pediatr 2017; 181S: S45–S51 e1. PubMed

Girodon-Boulandet E, Cazeneuve C, Goossens M. Screening practices for mutations in the CFTR gene ABCC7. Hum Mutat 2000; 15(2): 135–49. PubMed

Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol 2017; 129(3): e41–e55. PubMed

Zlotogora J, Israeli A. A comprehensive screening program for cystic fibrosis. Isr Med Assoc J 2009; 11(9): 555–7. PubMed

Janssens S, Kalokairinou L, Chokoshvilli D, et al. Attitudes of cystic fibrosis patients and their parents towards direct-to-consumer genetic testing for carrier status. Per Med 2015; 12(2): 99–107. PubMed

Thauvin-Robinet C, Munck A, Huet F, et al. CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders. J Med Genet 2013; 50(4): 220–7. PubMed

Harper JC, Aittomaki K, Borry P, et al. Recent developments in genetics and medically assisted reproduction: from research to clinical applications. Eur J Hum Genet 2018; 26(1): 12–33. PubMed PMC

Dequeker E, Stuhrmann M, Morris MA, et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations. Eur J Hum Genet 2009; 17(1): 51–65. PubMed PMC

Landaburu I, Gonzalvo MC, Clavero A, et al. Genetic testing of sperm donors for cystic fibrosis and spinal muscular atrophy: evaluation of clinical utility. Eur J Obstet Gynecol Reprod Biol 2013; 170(1): 183–7. PubMed

ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet Gynecol 2011; 117(4): 1028–31. PubMed

Morgan MA, Driscoll DA, Mennuti MT, Schulkin J. Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004; 6(5): 450–5. PubMed

Castellani C, Perobelli S, Bianchi V, et al. An interactive computer program can effectively educate potential users of cystic fibrosis carrier tests. Am J Med Genet A 2011; 155a(4): 778–85. PubMed

Braido F, Baiardini I, Sumberesi M, Canonica GW, Blasi F, Castellani C. Public awareness on cystic fibrosis: results from a national pragmatic survey. Eur Respir J 2015; 46(1): 264–7. PubMed

Metcalfe SA. Genetic counselling, patient education, and informed decision-making in the genomic era. Semin Fetal Neonatal Med 2018; 23(2): 142–9. PubMed

Castellani C, Massie J. Newborn screening and carrier screening for cystic fibrosis: alternative or complementary? Eur Respir J 2014; 43(1): 20–3. PubMed

Foil KE, Powers A, Raraigh KS, Wallis K, Southern KW, Salinas D. The increasing challenge of genetic counseling for cystic fibrosis. J Cyst Fibros 2019; 18(2): 167–74. PubMed

King JR, Klugman S. Ethnicity-Based Carrier Screening. Obstet Gynecol Clin North Am 2018; 45(1): 83–101. PubMed

Henneman L, Borry P, Chokoshvili D, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet 2016; 24(6): e1–e12. PubMed PMC

Girardet A, Viart V, Plaza S, et al. The improvement of the best practice guidelines for preimplantation genetic diagnosis of cystic fibrosis: toward an international consensus. Eur J Hum Genet 2016; 24(4): 469–78. PubMed PMC

Levy B, Stosic M. Traditional Prenatal Diagnosis: Past to Present. Methods Mol Biol 2019; 1885: 3–22. PubMed

Cunningham S, Marshall T. Influence of five years of antenatal screening on the paediatric cystic fibrosis population in one region. Arch Dis Child 1998; 78(4): 345–8. PubMed PMC

Scotet V, Dugueperoux I, Audrezet MP, et al. Focus on cystic fibrosis and other disorders evidenced in fetuses with sonographic finding of echogenic bowel: 16-year report from Brittany, France. Am J Obstet Gynecol 2010; 203(6): 592.e1–6. PubMed

Guissart C, Dubucs C, Raynal C, et al. Non-invasive prenatal diagnosis (NIPD) of cystic fibrosis: an optimized protocol using MEMO fluorescent PCR to detect the p.Phe508del mutation. J Cyst Fibros 2017; 16(2): 198–206. PubMed

Sosnay PR, Castellani C, Penland CM, et al. Bias in CFTR screening panels. Genet Med 2016; 18(2): 209. PubMed PMC

Holtkamp KCA, Mathijssen IB, Lakeman P, et al. Factors for successful implementation of population-based expanded carrier screening: learning from existing initiatives. Eur J Public Health 2017; 27(2): 372–7. PubMed PMC

Hetu M, Koutouki K, Joly Y. Genomics for All: International Open Science Genomics Projects and Capacity Building in the Developing World. Front Genet 2019; 10: 95. PubMed PMC

An JY. National human genome projects: an update and an agenda. Epidemiol Health 2017; 39: e2017045. PubMed PMC

http://www.genomeasia100k.com.

https://www.genomicsengland.co.uk/ (Accessed April 18, 2019).

https://www.genomicsengland.co.uk/wp-content/uploads/2018/07/black-african-black-caribbean-communities-participation-100kgp.pdf.

Loukas YL, Thodi G, Molou E, Georgiou V, Dotsikas Y, Schulpis KH. Clinical diagnostic Next-Generation sequencing: the case of CFTR carrier screening. Scand J Clin Lab Invest 2015; 75(5): 374–81. PubMed

Davis KF, D’Odorico P, Laio F, Ridolfi L. Global spatio-temporal patterns in human migration: a complex network perspective. PLoS One 2013; 8(1): e53723. PubMed PMC

Lamanna F, Lenormand M, Salas-Olmedo MH, Romanillos G, Goncalves B, Ramasco JJ. Immigrant community integration in world cities. PLoS One 2018; 13(3): e0191612. PubMed PMC

Steward CA, Parker APJ, Minassian BA, Sisodiya SM, Frankish A, Harrow J. Genome annotation for clinical genomic diagnostics: strengths and weaknesses. Genome Med 2017; 9(1): 49. PubMed PMC

Chen R, Shi L, Hakenberg J, et al. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat Biotechnol 2016; 34(5): 531–8. PubMed

Hui L, Bianchi DW. Prenatal pharmacotherapy for fetal anomalies: a 2011 update. Prenat Diagn 2011; 31(7): 735–43. PubMed PMC

Kauffman TL, Wilfond BS, Jarvik GP, et al. Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing. Contemp Clin Trials 2017; 53: 100–5. PubMed PMC

Khan MAZ, Konje JC. Ethical and religious dilemmas of modern reproductive choices and the Islamic perspective. Eur J Obstet Gynecol Reprod Biol 2019; 232: 5–9. PubMed

Dunne CP, Dunne SS. Personalized medicine should not be restricted to the wealthy. Nature 2018; 559(7712): 32. PubMed

Jackson AD, Goss CH. Epidemiology of CF: How registries can be used to advance our understanding of the CF population. J Cyst Fibros 2018; 17(3): 297–305. PubMed

Bobadilla JL, Macek M Jr., Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat 2002; 19(6): 575–606. PubMed

Banjar H, Angyalosi G. The road for survival improvement of cystic fibrosis patients in Arab countries. Int J Pediatr Adolesc Med 2015; 2(2): 47–58. PubMed PMC

Parker-Mc Gill K, Nugent M, Bersie R, et al. Changing incidence of cystic fibrosis in Wisconsin, USA. Pediatr Pulmonol 2015; 50(11): 1065–72. PubMed PMC

Alper OM, Wong LJ, Young S, et al. Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients. Hum Mutat 2004; 24(4): 353. PubMed

Scotet V, Dugueperoux I, Saliou P, et al. Evidence for decline in the incidence of cystic fibrosis: a 35-year observational study in Brittany, France. Orphanet J Rare Dis 2012; 7: 14. PubMed PMC

Stafler P, Mei-Zahav M, Wilschanski M, et al. The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening. J Cyst Fibros 2016; 15(4): 460–6. PubMed

Castellani C, Picci L, Tridello G, et al. Cystic fibrosis carrier screening effects on birth prevalence and newborn screening. Genet Med 2016; 18(2): 145–51. PubMed

Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008; 7(5): 450–3. PubMed

Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001; 3(2): 149–54. PubMed

https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Patient-Registry-Annual-Data-Report.pdf.

Jackson AD, Goss CH. Epidemiology of CF: How registries can be used to advance our understanding of the CF population. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017. PubMed

registry GC. https://www.muko.info/fileadmin/user_upload/angebote/qualitaetsmanagement/register/berichtsband_2017.pdf 2017.

registry UT. https://www.cysticfibrosis.org.uk/news/registry-report-2017. 2017.

registry CC. https://www.cysticfibrosis.ca/our-programs/cf-registry. 2017.

Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California. Chest 2016; 149(2): 380–9. PubMed PMC

Sykes J, Stanojevic S, Goss CH, et al. A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts. Journal of clinical epidemiology 2016; 70: 206–13. PubMed PMC

Stephenson AL, Sykes J, Stanojevic S, et al. Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study. Annals of internal medicine 2017. PubMed PMC

Goss CH, Sykes J, Stanojevic S, et al. Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. American journal of respiratory and critical care medicine 2018; 197(6): 768–75. PubMed PMC

George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342: d1008. PubMed PMC

Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011; 10 Suppl 2: S86–102. PubMed

Mayell SJ, Munck A, Craig JV, et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009; 8(1): 71–8. PubMed

Munck A, Mayell SJ, Winters V, et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 2015; 14(6): 706–13. PubMed

Cystic Fibrosis F, Borowitz D, Parad RB, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009; 155(6 Suppl): S106–16. PubMed PMC

Ren CL, Desai H, Platt M, Dixon M. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Pediatr Pulmonol 2011; 46(11): 1079–84. PubMed

Ooi CY, Castellani C, Keenan K, et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 2015; 135(6): e1377–85. PubMed

Barben J, Castellani C, Dankert-Roelse J, et al. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. J Cyst Fibros 2017; 16(2): 207–13. PubMed

Farrell PM, White TB, Howenstine MS, et al. Diagnosis of Cystic Fibrosis in Screened Populations. J Pediatr 2017; 181s: S33–S44.e2. PubMed

Sosnay PR, White TB, Farrell PM, et al. Diagnosis of Cystic Fibrosis in Nonscreened Populations. J Pediatr 2017; 181S: S52–S7 e2. PubMed

Worldbank. http://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html (Accessed May 8, 2019).

Camajova J, Berwouts S, Matthijs G, Macek M Jr., Dequeker E. Variability in the use of CE-marked assays for in vitro diagnostics of CFTR gene mutations in European genetic testing laboratories. Eur J Hum Genet 2009; 17(4): 537–40. PubMed PMC

Singh M, Rebordosa C, Bernholz J, Sharma N. Epidemiology and genetics of cystic fibrosis in Asia: In preparation for the next-generation treatments. Respirology 2015; 20(8): 1172–81. PubMed

Shen Y, Liu J, Zhong L, et al. Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children. J Pediatr 2016; 171: 269–76.e1. PubMed

Al-Sadeq D, Abunada T, Dalloul R, et al. Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review. Respirology 2019; 24(2): 127–36. PubMed

Biomed. www.bmbtrj.org/temp/BiomedBiotechnolResJ12105-5448768_150807.pdf

Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health 2009; 6: 17. PubMed PMC

Ibrahim SA, Fadl Elmola MA, Karrar ZA, et al. Cystic fibrosis in Sudanese children: First report of 35 cases. Sudan J Paediatr 2014; 14(1): 39–44. PubMed PMC

Bahrain. Bahrain Medical Bulletin 201; (23): 157–9.

Al-Gazali LI, Alwash R, Abdulrazzaq YM. United Arab Emirates: communities and community genetics. Community Genet 2005; 8(3): 186–96. PubMed

Dawson KP, Frossard PM. Cystic fibrosis in the Middle East: the historical perspective. Ann Saudi Med 2000; 20(1): 20–3. PubMed

Maps G. http://gulf2000.columbia.edu/maps.shtml.

Desgeorges M, Megarbane A, Guittard C, et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. Hum Genet 1997; 100(2): 279–83. PubMed

Alibakhshi R, Kianishirazi R, Cassiman JJ, Zamani M, Cuppens H. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. J Cyst Fibros 2008; 7(2): 102–9. PubMed

Koomesh. http://koomeshjournal.semums.ac.ir/browse.php?a_code=A-10-2167-1&slc_lang=fa&sid=1

Issa AR, Teebi AS, Issa MA, Shaabani IS, Ramadan DJ. Metabolic alkalosis in cystic fibrosis: atypical presentation in Kuwait. Ann Trop Paediatr 1988; 8(4): 271–2. PubMed

Dahabreh MM, Najada AS. Pseudo-bartter syndrome, pattern and correlation with other cystic fibrosis features. Saudi J Kidney Dis Transpl 2013; 24(2): 292–6. PubMed

Banjar HH. Cystic fibrosis: presentation with other diseases, the experience in Saudi Arabia. J Cyst Fibros 2003; 2(3): 155–9. PubMed

Al-Gazali L, Ali BR. Mutations of a country: a mutation review of single gene disorders in the United Arab Emirates (UAE). Hum Mutat 2010; 31(5): 505–20. PubMed

Koshy R, Sivadas A, Scaria V. Genetic epidemiology of familial Mediterranean fever through integrative analysis of whole genome and exome sequences from Middle East and North Africa. Clin Genet 2018; 93(1): 92–102. PubMed

Stewart C, Pepper MS. Cystic fibrosis on the African continent. Genet Med 2016; 18(7): 653–62. PubMed

Van Rensburg J, Alessandrini M, Stewart C, Pepper MS. Cystic fibrosis in South Africa: A changing diagnostic paradigm. S Afr Med J 2018; 108(8): 624–8. PubMed

Zampoli On Behalf Of The Msac M. Cystic fibrosis: What’s new in South Africa in 2019. S Afr Med J 2018; 109(1): 16–9. PubMed

Wang SS, O’Leary LA, Fitzsimmons SC, Khoury MJ. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002; 141(6): 804–10. PubMed

Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008; 9: 403–33. PubMed PMC

Akombi BJ, Agho KE, Merom D, Renzaho AM, Hall JJ. Child malnutrition in sub-Saharan Africa: A meta-analysis of demographic and health surveys (2006–2016). PLoS One 2017; 12(5): e0177338. PubMed PMC

Slagle T, Ben Youssef M, Calonge G, Ben Amor Y. Lessons from Africa: developing a global human rights framework for tuberculosis control and prevention. BMC Int Health Hum Rights 2014; 14: 34. PubMed PMC

Reid SR. Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review. Harm Reduct J 2009; 6: 24. PubMed PMC

Adhikari K, Mendoza-Revilla J, Chacon-Duque JC, Fuentes-Guajardo M, Ruiz-Linares A. Admixture in Latin America. Curr Opin Genet Dev 2016; 41: 106–14. PubMed

Norris ET, Wang L, Conley AB, et al. Genetic ancestry, admixture and health determinants in Latin America. BMC Genomics 2018; 19(Suppl 8): 861. PubMed PMC

Alonso MJ, Heine-Suner D, Calvo M, et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. Ann Hum Genet 2007; 71(Pt 2): 194–201. PubMed

Perez MM, Luna MC, Pivetta OH, Keyeux G. CFTR gene analysis in Latin American CF patients: heterogeneous origin and distribution of mutations across the continent. J Cyst Fibros 2007; 6(3): 194–208. PubMed

Stewart C, Pepper MS. Cystic Fibrosis in the African Diaspora. Ann Am Thorac Soc 2017; 14(1): 1–7. PubMed

Conway S, Balfour-Lynn IM, De Rijcke K, et al. European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. J Cyst Fibros 2014; 13 Suppl 1: S3–22. PubMed PMC

Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS. Key findings of the US Cystic Fibrosis Foundation’s clinical practice benchmarking project. BMJ Qual Saf 2014; 23 Suppl 1: i15–i22. PubMed

Young DC, Autry E, Zobell JT, et al. Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics. Pediatr Pulmonol 2019. PubMed

Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13 Suppl 1: S23–42. PubMed

Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018; 17(2): 153–78. PubMed

Elborn JS, Bell SC, Madge SL, et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J 2016; 47(2): 420–8. PubMed

Farrell PM, Lai HJ, Li Z, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005; 147(3 Suppl): S30–6. PubMed

Sanders DB, Zhang Z, Farrell PM, Lai HJ, Wisconsin CFNSG. Early life growth patterns persist for 12years and impact pulmonary outcomes in cystic fibrosis. J Cyst Fibros 2018; 17(4): 528–35. PubMed PMC

Cystic Fibrosis F, Borowitz D, Robinson KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155(6 Suppl): S73–93. PubMed PMC

Esther CR Jr., Muhlebach MS, Ehre C, et al. Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis. Sci Transl Med 2019; 11(486). PubMed PMC

Ranganathan SC, Hall GL, Sly PD, Stick SM, Douglas TA, Australian Respiratory Early Surveillance Team for Cystic F. Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It? Am J Respir Crit Care Med 2017; 195(12): 1567–75. PubMed PMC

Nguyen TT, Thia LP, Hoo AF, et al. Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants. Thorax 2014; 69(10): 910–7. PubMed PMC

Bush A, Sly PD. Evolution of cystic fibrosis lung function in the early years. Curr Opin Pulm Med 2015; 21(6): 602–8. PubMed

Rosenow T, Mok LC, Turkovic L, et al. The cumulative effect of inflammation and infection on structural lung disease in early CF. Eur Respir J 2019. PubMed

Deschamp AR, Hatch JE, Slaven JE, et al. Early respiratory viral infections in infants with cystic fibrosis. J Cyst Fibros 2019. PubMed PMC

Eyns H, Pierard D, De Wachter E, Eeckhout L, Vaes P, Malfroot A. Respiratory Bacterial Culture Sampling in Expectorating and Non-expectorating Patients With Cystic Fibrosis. Front Pediatr 2018; 6: 403. PubMed PMC

Doumit M, Belessis Y, Stelzer-Braid S, Mallitt KA, Rawlinson W, Jaffe A. Diagnostic accuracy and distress associated with oropharyngeal suction in cystic fibrosis. J Cyst Fibros 2016; 15(4): 473–8. PubMed

Equi AC, Pike SE, Davies J, Bush A. Use of cough swabs in a cystic fibrosis clinic. Arch Dis Child 2001; 85(5): 438–9. PubMed PMC

Ferreira ACM, Marson FAL, Cohen MA, et al. Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis. Lung 2017; 195(4): 431–9. PubMed

Ahmed MI, Kulkarni H, Shajpal S, et al. Early detection of non-tuberculous mycobacteria in children with cystic fibrosis using induced sputum at annual review. Pediatr Pulmonol 2019; 54(3): 257–63. PubMed

Ronchetti K, Tame JD, Paisey C, et al. The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med 2018; 6(6): 461–71. PubMed PMC

Zampoli M, Pillay K, Carrara H, Zar HJ, Morrow B. Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis. J Cyst Fibros 2016; 15(5): 605–10. PubMed

Rosenfeld M, Allen J, Arets BH, et al. An official American Thoracic Society workshop report: optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and recurrent wheezing in children less than 6 years of age. Ann Am Thorac Soc 2013; 10(2): S1–S11. PubMed

Davies G, Stocks J, Thia LP, et al. Pulmonary function deficits in newborn screened infants with cystic fibrosis managed with standard UK care are mild and transient. Eur Respir J 2017; 50(5). PubMed

Robinson PD, Latzin P, Ramsey KA, et al. Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med 2018; 197(5): e1–e19. PubMed

Saunders C, Bayfield K, Irving S, Short C, Bush A, Davies JC. Developments in multiple breath washout testing in children with cystic fibrosis. Curr Med Res Opin 2017; 33(4): 613–20. PubMed

Stanojevic S, Davis SD, Retsch-Bogart G, et al. Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. Am J Respir Crit Care Med 2017; 195(9): 1216–25. PubMed PMC

Owens CM, Aurora P, Stanojevic S, et al. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax 2011; 66(6): 481–8. PubMed

Lum S, Gustafsson P, Ljungberg H, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007; 62(4): 341–7. PubMed PMC

https://lab.research.sickkids.ca/ratjen/.

https://www.ecfs.eu/ctn/lci/lci-core-facility-definition;.

Stahl M, Joachim C, Wielputz MO, Mall MA. Comparison of lung clearance index determined by washout of N2 and SF6 in infants and preschool children with cystic fibrosis. J Cyst Fibros 2018. PubMed

Sakarya A, Uyan ZS, Baydemir C, et al. Evaluation of children with cystic fibrosis by impulse oscillometry when stable and at exacerbation. Pediatr Pulmonol 2016; 51(11): 1151–8. PubMed

Buchs C, Coutier L, Vrielynck S, Jubin V, Mainguy C, Reix P. An impulse oscillometry system is less efficient than spirometry in tracking lung function improvements after intravenous antibiotic therapy in pediatric patients with cystic fibrosis. Pediatr Pulmonol 2015; 50(11): 1073–81. PubMed

Lin S, Lin M, Lau KK. Efficacy of model-based iterative reconstruction in cystic fibrosis assessment using CT. Clin Radiol 2019. PubMed

Mall MA, Stahl M, Graeber SY, Sommerburg O, Kauczor HU, Wielputz MO. Early detection and sensitive monitoring of CF lung disease: Prospects of improved and safer imaging. Pediatr Pulmonol 2016; 51(S44): S49–S60. PubMed

Rayment JH, Couch MJ, McDonald N, et al. Hyperpolarised (129)Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis. Eur Respir J 2019; 53(5). PubMed

Martini K, Gygax CM, Benden C, Morgan AR, Parker GJM, Frauenfelder T. Volumetric dynamic oxygen-enhanced MRI (OE-MRI): comparison with CT Brody score and lung function in cystic fibrosis patients. Eur Radiol 2018; 28(10): 4037–47. PubMed

Wielputz MO, Eichinger M, Wege S, et al. Mid-Term Reproducibility of Chest MRI in Adults with Clinically Stable Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2019. PubMed

Rand S, Hill L, Prasad SA. Physiotherapy in cystic fibrosis: optimising techniques to improve outcomes. Paediatr Respir Rev 2013; 14(4): 263–9. PubMed

Flume PA, Robinson KA, O’Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009; 54(4): 522–37. PubMed

Ward N, Stiller K, Holland AE. Exercise as a therapeutic intervention for people with cystic fibrosis. Expert Rev Respir Med 2019; 13(5): 449–58. PubMed

Acosta N, Heirali A, Somayaji R, et al. Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis. Thorax 2018; 73(11): 1016–25. PubMed

Khan MA, Ali ZS, Sweezey N, Grasemann H, Palaniyar N. Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. Genes (Basel) 2019; 10(3). PubMed PMC

Sanders DB, Emerson J, Ren CL, et al. Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. Ann Am Thorac Soc 2015; 12(8): 1170–6. PubMed PMC

Oates GR, Schechter MS. Socioeconomic status and health outcomes: cystic fibrosis as a model. Expert Rev Respir Med 2016; 10(9): 967–77. PubMed

Breuer O, Caudri D, Stick S, Turkovic L. Predicting disease progression in cystic fibrosis. Expert Rev Respir Med 2018; 12(11): 905–17. PubMed

Sherrard LJ, Bell SC. Lower airway microbiota for ‘biomarker’ measurements of cystic fibrosis disease progression? Thorax 2018; 73(11): 1001–3. PubMed

Scott LK, Toner R. Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations. Lung 2017; 195(4): 397–401. PubMed

Nick JA, Sanders LA, Ickes B, et al. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. Thorax 2013; 68(10): 929–37. PubMed

Liou TG, Adler FR, Argel N, et al. Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Med Res Methodol 2019; 19(1): 88. PubMed PMC

Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354(3): 229–40. PubMed

Stahl M, Wielputz MO, Ricklefs I, et al. Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study. Am J Respir Crit Care Med 2019; 199(10): 1238–48. PubMed

Mogayzel PJ Jr., Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc 2014; 11(10): 1640–50. PubMed

Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 2016; 4(2): 107–15. PubMed PMC

Rosenfeld M, Cunningham S, Harris WT, et al. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5years (KLIMB). J Cyst Fibros 2019. PubMed PMC

Christian F, Thierman A, Shirley E, Allen K, Cross C, Jones K. Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes. J Investig Med High Impact Case Rep 2019; 7: 2324709619842898. PubMed PMC

Kelly A, De Leon DD, Sheikh S, et al. Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy. Am J Respir Crit Care Med 2019; 199(3): 342–51. PubMed PMC

Hayes D Jr., McCoy KS, Sheikh SI. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med 2014; 190(5): 590–1. PubMed

Bellin MD, Laguna T, Leschyshyn J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013; 14(6): 417–21. PubMed PMC

Ren CL, Borowitz DS, Gonska T, et al. Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis. J Pediatr 2017; 181s: S45–S51.e1. PubMed

Hayeems RZ, Miller FA, Vermeulen M, et al. False-Positive Newborn Screening for Cystic Fibrosis and Health Care Use. Pediatrics 2017; 140(5). PubMed

Caverly LJ, LiPuma JJ. Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice. Expert Rev Respir Med 2018; 12(10): 857–65. PubMed PMC

Carmody LA, Caverly LJ, Foster BK, et al. Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. PLoS One 2018; 13(3): e0194060. PubMed PMC

Zemanick ET, Wagner BD, Robertson CE, et al. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J 2017; 50(5). PubMed PMC

Schaffer K. Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients. J Hosp Infect 2015; 89(4): 309–13. PubMed

Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. American journal of respiratory and critical care medicine 2012; 185(2): 231–2. PubMed

Johnston DI, Chisty Z, Gross JE, Park SY. Investigation of Mycobacterium abscessus outbreak among cystic fibrosis patients, Hawaii 2012. The Journal of hospital infection 2016; 94(2): 198–200. PubMed

Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet (London, England) 2013; 381(9877): 1551–60. PubMed PMC

Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science (New York, NY) 2016; 354(6313): 751–7. PubMed PMC

Engel TGP, Erren E, Vanden Driessche KSJ, et al. Aerosol Transmission of Aspergillus fumigatus in Cystic Fibrosis Patients in the Netherlands. Emerging infectious diseases 2019; 25(4): 797–9. PubMed PMC

Kerem E, Conway S, Elborn S, Heijerman H, Consensus C. Standards of care for patients with cystic fibrosis: a European consensus. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2005; 4(1): 7–26. PubMed

Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infection control and hospital epidemiology 2014; 35 Suppl 1: S1–S67. PubMed

Stoudemire W, Jiang X, Zhou JJ, et al. Cystic fibrosis program characteristics associated with adoption of 2013 infection prevention and control recommendations. American journal of infection control 2019. PubMed

Rowbotham NJ, Palser SC, Smith SJ, Smyth AR. Infection prevention and control in cystic fibrosis: a systematic review of interventions. Expert review of respiratory medicine 2019; 13(5): 425–34. PubMed

Smyth AR, Rosenfeld M. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2017; 4: CD001912. PubMed PMC

Ratjen F, Comes G, Paul K, et al. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001; 31(1): 13–6. PubMed

http://www.cfstart.org.uk/.

Gramegna A, Moore JE, McCaughan J, et al. Increasing Burden of Antimicrobial Resistance in Pseudomonas Aeruginosa from Adult Patients with Cystic Fibrosis (Cf) in Northern Ireland: Then and Now. The Ulster medical journal 2018; 87(2): 129–30. PubMed PMC

Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 2014; 384(9944): 703–13. PubMed

Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrobial agents and chemotherapy 2012; 56(2): 869–74. PubMed PMC

Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123(5): 1495–502. PubMed

Aaron SD, Chaparro C. Referral to lung transplantation--too little, too late. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2016; 15(2): 143–4. PubMed

Jorth P, Staudinger BJ, Wu X, et al. Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. Cell host & microbe 2015; 18(3): 307–19. PubMed PMC

Somayaji R, Parkins MD, Shah A, et al. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2019; 18(2): 236–43. PubMed

Kidd TJ, Canton R, Ekkelenkamp M, et al. Defining antimicrobial resistance in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018; 17(6): 696–704. PubMed

Waters VJ, Kidd TJ, Canton R, et al. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019. PubMed

Qvist T, Johansen IS, Pressler T, et al. Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria--experiences from the Danish Cystic Fibrosis cohort study. BMC Infect Dis 2014; 14: 655. PubMed PMC

Songkhla MN, Tantipong H, Tongsai S, Angkasekwinai N. Lateral Flow Urine Lipoarabinomannan Assay for Diagnosis of Active Tuberculosis in Adults With Human Immunodeficiency Virus Infection: A Prospective Cohort Study. Open Forum Infect Dis 2019; 6(4): ofz132. PubMed PMC

Sanchez C, Santos JP, Lozano J. Use of Electronic Noses for Diagnosis of Digestive and Respiratory Diseases through the Breath. Biosensors (Basel) 2019; 9(1). PubMed PMC

Christiansen A, Davidsen JR, Titlestad I, Vestbo J, Baumbach J. A systematic review of breath analysis and detection of volatile organic compounds in COPD. J Breath Res 2016; 10(3): 034002. PubMed

Smith WD, Bardin E, Cameron L, et al. Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS Microbiol Lett 2017; 364(14). PubMed

Moheet A, Moran A. CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis. Pediatr Pulmonol 2017; 52(S48): S37–S43. PubMed

Bridges N, Rowe R, Holt RIG. Unique challenges of cystic fibrosis-related diabetes. Diabet Med 2018. PubMed

Moheet A, Moran A. Pharmacological management of cystic fibrosis related diabetes. Expert Rev Clin Pharmacol 2018; 11(2): 185–91. PubMed

West NE, Flume PA. Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Rev Respir Med 2018; 12(7): 585–93. PubMed PMC

Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 2005; 6: 237–60. PubMed

Waters V, Ratjen F. Pulmonary Exacerbations in Children with Cystic Fibrosis. Ann Am Thorac Soc 2015; 12 Suppl 2: S200–6. PubMed

Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes 2016; 14: 63. PubMed PMC

Habib AR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS. A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc 2015; 12(3): 420–8. PubMed

Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182(5): 627–32. PubMed PMC

Cogen J, Emerson J, Sanders DB, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 2015; 50(8): 763–70. PubMed PMC

Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40(1): 61–6. PubMed

Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46(4): 393–400. PubMed

Plummer A, Wildman M, Gleeson T. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2016; 9: CD006682. PubMed PMC

Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2017; 10: CD009528. PubMed PMC

Aaron SD. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev 2007; 8(3): 256–61. PubMed

Serisier DJ, Tuck A, Matley D, Carroll MP, Jones G. Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing. Eur J Clin Microbiol Infect Dis 2012; 31(11): 3211–6. PubMed

Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013; 144(5): 1659–70. PubMed

Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2018; 9: CD001506. PubMed PMC

Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012; 11: CD002203. PubMed PMC

Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database Syst Rev 2015; (3): CD009841. PubMed

Goralski JL, Nasr SZ, Uluer A. Overcoming barriers to a successful transition from pediatric to adult care. Pediatr Pulmonol 2017; 52(S48): S52–S60. PubMed

Six Core Elements of Health Care Transition.

Gleeson H, McCartney S, Lidstone V. ‘Everybody’s business’: transition and the role of adult physicians. Clin Med (Lond) 2012; 12(6): 561–6. PubMed PMC

ON TRAC TRANSITION CLINICAL PATHWAY.

Keating CL, Liu X, Dimango EA. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. Chest 2010; 137(5): 1157–63. PubMed PMC

Desai S, Wong H, Sykes J, Stephenson AL, Singer J, Quon BS. Clinical Characteristics and Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis. Analysis of the Canadian CF Registry. Ann Am Thorac Soc 2018; 15(10): 1177–85. PubMed

De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61(7): 627–35. PubMed PMC

Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35(3): 557–77. PubMed

Panagopoulou P, Fotoulaki M, Nikolaou A, Nousia-Arvanitakis S. Prevalence of malnutrition and obesity among cystic fibrosis patients. Pediatr Int 2014; 56(1): 89–94. PubMed

Lewis C, Blackman SM, Nelson A, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med 2015; 191(2): 194–200. PubMed PMC

Regard L, Martin C, Chassagnon G, Burgel PR. Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Rev Respir Med 2019; 13(1): 23–38. PubMed

Safaeian M, Robbins HA, Berndt SI, Lynch CF, Fraumeni JF Jr., Engels EA. Risk of Colorectal Cancer After Solid Organ Transplantation in the United States. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2016; 16(3): 960–7. PubMed PMC

Fink AK, Yanik EL, Marshall BC, et al. Cancer risk among lung transplant recipients with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017; 16(1): 91–7. PubMed PMC

Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. Journal of the National Cancer Institute 2003; 95(5): 381–7. PubMed

Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. Journal of the National Cancer Institute 2013; 105(2): 122–9. PubMed

Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol 2018; 19(6): 758–67. PubMed

Hadjiliadis D, Khoruts A, Zauber AG, et al. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology 2018; 154(3): 736–45 e14. PubMed PMC

Dai Z, Coker OO, Nakatsu G, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome 2018; 6(1): 70. PubMed PMC

Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017; 16 Suppl 2: S14–S23. PubMed

Zhang J, Wang Y, Jiang X, Chan HC. Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer. Cellular and molecular life sciences : CMLS 2018; 75(10): 1737–56. PubMed PMC

Than BLN, Linnekamp JF, Starr TK, et al. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 2017; 36(24): 3504. PubMed

Berg KH, Ryom L, Faurholt-Jepsen D, Pressler T, Katzenstein TL. Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018; 17(4): 478–83. PubMed

Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR, Goss CH. Risk factors for chronic kidney disease in adults with cystic fibrosis. American journal of respiratory and critical care medicine 2011; 184(10): 1147–52. PubMed PMC

Yahiaoui Y, Jablonski M, Hubert D, et al. Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. Clinical journal of the American Society of Nephrology : CJASN 2009; 4(5): 921–8. PubMed PMC

Lefaucheur C, Nochy D, Amrein C, et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008; 8(9): 1901–10. PubMed

Gonzalez Jimenez D, Munoz-Codoceo R, Garriga-Garcia M, et al. [Excess weight in patients with cystic fibrosis: is it always beneficial?]. Nutricion hospitalaria 2017; 34(3): 578–83. PubMed

Stephenson AL, Mannik LA, Walsh S, et al. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. The American journal of clinical nutrition 2013; 97(4): 872–7. PubMed

Snell G, Reed A, Stern M, Hadjiliadis D. The evolution of lung transplantation for cystic fibrosis: A 2017 update. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017; 16(5): 553–64. PubMed

Thabut G, Christie JD, Mal H, et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. American journal of respiratory and critical care medicine 2013; 187(12): 1335–40. PubMed PMC

Ramos KJ, Quon BS, Psoter KJ, et al. Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2016; 15(2): 196–203. PubMed PMC

Quon BS, Psoter K, Mayer-Hamblett N, Aitken ML, Li CI, Goss CH. Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status. American journal of respiratory and critical care medicine 2012; 186(10): 1008–13. PubMed PMC

Martin C, Hamard C, Kanaan R, et al. Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies! J Cyst Fibros 2016; 15(2): 204–12. PubMed

Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326(18): 1187–91. PubMed

Yankaskas JR, Mallory GB Jr., Lung transplantation in cystic fibrosis: consensus conference statement. Chest 1998; 113(1): 217–26. PubMed

Ramos KJ, Quon BS, Heltshe SL, et al. Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States. Chest 2017; 151(6): 1320–8. PubMed PMC

Aaron SD, Stephenson AL, Cameron DW, Whitmore GA. A statistical model to predict one-year risk of death in patients with cystic fibrosis. Journal of clinical epidemiology 2015; 68(11): 1336–45. PubMed

Nkam L, Lambert J, Latouche A, Bellis G, Burgel PR, Hocine MN. A 3-year prognostic score for adults with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017; 16(6): 702–8. PubMed

Coriati A, Sykes J, Nkam L, Hocine MN, Burgel PR, Stephenson AL. Validation of the French 3- year prognostic score using the Canadian Cystic Fibrosis registry. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018. PubMed

Alaa AM, van der Schaar M. Prognostication and Risk Factors for Cystic Fibrosis via Automated Machine Learning. Sci Rep 2018; 8(1): 11242. PubMed PMC

Ramos KJ, Somayaji R, Lease ED, Goss CH, Aitken ML. Cystic fibrosis physicians’ perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States. BMC pulmonary medicine 2017; 17(1): 21. PubMed PMC

Ramos KJ, Hobler MR, Engelberg RA, et al. Addressing lung transplant with adults with cystic fibrosis: A qualitative analysis of patients’ perspectives and experiences. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2019. PubMed PMC

Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2019. PubMed PMC

Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006; 6(5 Pt 2): 1212–27. PubMed

Li SS, Miller R, Tumin D, Stewart WCL, Tobias JD, Hayes D Jr., Lung Allocation Score Thresholds Prioritize Survival After Lung Transplantation. Chest 2019. PubMed

Braun AT, Dasenbrook EC, Shah AS, Orens JB, Merlo CA. Impact of lung allocation score on survival in cystic fibrosis lung transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2015; 34(11): 1436–41. PubMed PMC

Roux A, Beaumont-Azuar L, Hamid AM, et al. High Emergency Lung Transplantation: dramatic decrease of waiting list death rate without relevant higher post-transplant mortality. Transplant international : official journal of the European Society for Organ Transplantation 2015; 28(9): 1092–101. PubMed

Boussaud V, Mal H, Trinquart L, et al. One-year experience with high-emergency lung transplantation in France. Transplantation 2012; 93(10): 1058–63. PubMed

Chaparro C, Keshavjee S. Lung transplantation for cystic fibrosis: an update. Expert review of respiratory medicine 2016; 10(12): 1269–80. PubMed

Urquhart DS, Thia LP, Francis J, et al. Deaths in childhood from cystic fibrosis: 10-year analysis from two London specialist centres. Arch Dis Child 2013; 98(2): 123–7. PubMed

McCormick J, Mehta G, Olesen HV, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010; 375(9719): 1007–13. PubMed

ECFS Patient Registry: Annual Data Report 2016.

Blasi F, Elborn JS, Palange P. Adults with cystic fibrosis and pulmonologists: new training needed to recruit future specialists. Eur Respir J 2019; 53(1). PubMed

Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005; 4: 7–26. PubMed

Balaguer A, Gonzalez de Dios J. Home versus hospital intravenous antibiotic therapy for cystic fibrosis. The Cochrane database of systematic reviews 2015; (12): CD001917. PubMed PMC

Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr., Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010; 182(9): 1137–43. PubMed PMC

Burgess JC, Bridges N, Banya W, et al. HbA1c as a screening tool for cystic fibrosis related diabetes. J Cyst Fibros 2016; 15(2): 251–7. PubMed

Burnet E, Hubert D, Champreux J, et al. A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre. J Cyst Fibros 2018; 17(5): 636–42. PubMed

registry B. Registro Brasileiro de Fibrose Cistica 2016.

www.cfww.org.

Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry. Int J Environ Res Public Health 2018; 15(9). PubMed PMC

Mehta G, Macek M Jr., Mehta A, European Registry Working G. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros 2010; 9 Suppl 2: S5–S21. PubMed

Madge S, Bell SC, Burgel PR, et al. Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. J Cyst Fibros 2017; 16(1): 85–8. PubMed

Walicka-Serzysko K, Peckova M, Noordhoek JJ, Sands D, Drevinek P. Insights into the cystic fibrosis care in Eastern Europe: Results of survey. J Cyst Fibros 2018; 17(4): 475–7. PubMed

Rodrigues ME, Melo MC, Reis FJ, Penna FJ. Concentration of electrolytes in the sweat of malnourished children. Arch Dis Child 1994; 71(2): 141–3. PubMed PMC

Yigit H, Selimoglu MA, Altinkaynak S. Sweat test results in children with primary protein energy malnutrition. J Pediatr Gastroenterol Nutr 2003; 37(3): 242–5. PubMed

Mutesa L, Azad AK, Verhaeghe C, et al. Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants. Chest 2009; 135(5): 1233–42. PubMed

Mattar AC, Leone C, Rodrigues JC, Adde FV. Sweat conductivity: an accurate diagnostic test for cystic fibrosis? Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2014; 13(5): 528–33. PubMed

Lezana JL, Vargas MH, Karam-Bechara J, Aldana RS, Furuya ME. Sweat conductivity and chloride titration for cystic fibrosis diagnosis in 3834 subjects. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2003; 2(1): 1–7. PubMed

Zampoli M. Cystic fibrosis: What’s new in South Africa in 2019. SAMJ: South African Medical Journal 2019; 109(1): 16–9. PubMed

Liu J, Lewinger JP, Gilliland FD, Gauderman WJ, Conti DV. Confounding and heterogeneity in genetic association studies with admixed populations. Am J Epidemiol 2013; 177(4): 351–60. PubMed PMC

Ruiz-Cabezas JC, Barros F, Sobrino B, et al. Mutational analysis of CFTR in the Ecuadorian population using next-generation sequencing. Gene 2019; 696: 28–32. PubMed

Gutierrez HH, Sanchez I, Schidlow DV. Cystic fibrosis care in Chile. Curr Opin Pulm Med 2009; 15(6): 632–7. PubMed

Mogayzel PJ Jr., Dunitz J, Marrow LC, Hazle LA. Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network. BMJ Qual Saf 2014; 23 Suppl 1: i3–8. PubMed

Sabadosa KA, Godfrey MM, Marshall BC. Trans-Atlantic collaboration: applying lessons learned from the US CF Foundation quality improvement initiative. Orphanet J Rare Dis 2018; 13(Suppl 1): 13. PubMed PMC

Nelson EC, Batalden PB, Mohr JJ, Plume SK. Building a quality future. Front Health Serv Manage 1998; 15(1): 3–32. PubMed

Godfrey MM, Oliver BJ. Accelerating the rate of improvement in cystic fibrosis care: contributions and insights of the learning and leadership collaborative. BMJ Qual Saf 2014; 23 Suppl 1: i23–i32. PubMed

Marshall BC, Nelson EC. Accelerating implementation of biomedical research advances: critical elements of a successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative. BMJ Qual Saf 2014; 23 Suppl 1: i95–i103. PubMed

Schweitzer SO, Comanor WS. Prices of pharmaceuticals in poor countries are much lower than in wealthy countries. Health Aff (Millwood) 2011; 30(8): 1553–61. PubMed

Patel MR, Press VG, Gerald LB, et al. Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med 2018; 198(11): 1367–74. PubMed

Kremer M. Pharmaceuticals and the developing world. J Econ Perspect 2002; 16(4): 67–90. PubMed

Matel JL, Milla CE. Nutrition in cystic fibrosis. Semin Respir Crit Care Med 2009; 30(5): 579–86. PubMed

Cohen-Cymberknoh M, Shoseyov D, Breuer O, Shamali M, Wilschanski M, Kerem E. Treatment of cystic fibrosis in low-income countries. Lancet Respir Med 2016; 4(2): 91–2. PubMed

McIlwaine M, Button B, Dwan K. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2015; (6): CD003147. PubMed

Prescott WA Jr., A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Respir Care 2014; 59(9): 1353–9. PubMed

Nikolaizik WH, Vietzke D, Ratjen F. A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. Can Respir J 2008; 15(5): 259–62. PubMed PMC

Fink AK, Loeffler DR, Marshall BC, Goss CH, Morgan WJ. Data that empower: The success and promise of CF patient registries. Pediatr Pulmonol 2017; 52(S48): S44–S51. PubMed

Muller I, Smith T, Mellor S, Rare L, Genton B. The effect of distance from home on attendance at a small rural health centre in Papua New Guinea. Int J Epidemiol 1998; 27(5): 878–84. PubMed

Okwaraji YB, Edmond KM. Proximity to health services and child survival in low- and middle-income countries: a systematic review and meta-analysis. BMJ Open 2012; 2(4). PubMed PMC

Clark RA, Coffee N, Turner D, et al. Application of geographic modeling techniques to quantify spatial access to health services before and after an acute cardiac event: the Cardiac Accessibility and Remoteness Index for Australia (ARIA) project. Circulation 2012; 125(16): 2006–14. PubMed

Kapwata T, Manda S. Geographic assessment of access to health care in patients with cardiovascular disease in South Africa. BMC Health Serv Res 2018; 18(1): 197. PubMed PMC

Zeng W, Li G, Ahn H, Nguyen HTH, Shepard DS, Nair D. Cost-effectiveness of health systems strengthening interventions in improving maternal and child health in low- and middle-income countries: a systematic review. Health Policy Plan 2018; 33(2): 283–97. PubMed

Martinez-Millana A, Zettl A, Floch J, et al. The Potential of Self-Management mHealth for Pediatric Cystic Fibrosis: Mixed-Methods Study for Health Care and App Assessment. JMIR Mhealth Uhealth 2019; 7(4): e13362. PubMed PMC

Hilliard ME, Hahn A, Ridge AK, Eakin MN, Riekert KA. User Preferences and Design Recommendations for an mHealth App to Promote Cystic Fibrosis Self-Management. JMIR Mhealth Uhealth 2014; 2(4): e44. PubMed PMC

http://portalgbefc.org.br/.

http://www.sacfa.org.za/.

Taylor-Robinson D, Schechter MS. Health inequalities and cystic fibrosis. BMJ 2011; 343: d4818. PubMed

Taylor-Robinson DC, Smyth RL, Diggle PJ, Whitehead M. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study. Lancet Respir Med 2013; 1(2): 121–8. PubMed PMC

Van Stormbroek B, Zampoli M, Morrow BM. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2019; 54(4): 393–8. PubMed

Vahedi L, Jabarpoor-Bonyadi M, Ghojazadeh M, Hazrati H, Rafeey M. Association Between Outcomes and Demographic Factors in an Azeri Turkish Population With Cystic Fibrosis: A Cross-Sectional Study in Iran From 2001 Through 2014. Iran Red Crescent Med J 2016; 18(4): e29615. PubMed PMC

Roberts JM, Wilcox PG, Quon BS. Evaluating Adult Cystic Fibrosis Care in BC: Disparities in Access to a Multidisciplinary Treatment Centre. Can Respir J 2016; 2016: 8901756. PubMed PMC

Thomas CL, O’Rourke PK, Wainwright CE. Clinical outcomes of Queensland children with cystic fibrosis: a comparison between tertiary centre and outreach services. Med J Aust 2008; 188(3): 135–9. PubMed

Wood J, Mulrennan S, Hill K, Cecins N, Morey S, Jenkins S. Telehealth clinics increase access to care for adults with cystic fibrosis living in rural and remote Western Australia. J Telemed Telecare 2017; 23(7): 673–9. PubMed

Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009; 106(44): 18825–30. PubMed PMC

Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A 2013; 110(11): 4404–9. PubMed PMC

Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 2012; 287(44): 36639–49. PubMed PMC

Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 2001; 281(5): C1734–42. PubMed

Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115(9): 2564–71. PubMed PMC

Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108(46): 18843–8. PubMed PMC

Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290(6): L1117–30. PubMed

Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363(21): 1991–2003. PubMed PMC

Graeber SY, Hug MJ, Sommerburg O, et al. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Am J Respir Crit Care Med 2015; 192(10): 1252–5. PubMed

Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190(2): 175–84. PubMed PMC

Ponzano S, Nigrelli G, Fregonese L, et al. A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators. Eur Respir Rev 2018; 27(148). PubMed PMC

Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014; 13(1): 29–36. PubMed

Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11(3): 237–45. PubMed

Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013; 45(10): 1160–7. PubMed PMC

Ratner M. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label. Nat Biotechnol 2017; 35(7): 606. PubMed

Sun X, Yi Y, Yan Z, et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med 2019; 11(485). PubMed PMC

Rosenfeld M, Wainwright CE, Higgins M, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 2018; 6(7): 545–53. PubMed PMC

Bessonova L, Volkova N, Higgins M, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax 2018; 73(8): 731–40. PubMed PMC

Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. Cell 2012; 148(1–2): 150–63. PubMed PMC

Mendoza JL, Schmidt A, Li Q, et al. Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell 2012; 148(1–2): 164–74. PubMed PMC

Wang C, Protasevich I, Yang Z, et al. Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. Protein Sci 2010; 19(10): 1932–47. PubMed PMC

Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67(1): 12–8. PubMed PMC

Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012; 142(3): 718–24. PubMed PMC

Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014; 2(7): 527–38. PubMed

Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med 2017; 377(21): 2013–23. PubMed

Donaldson SH, Pilewski JM, Griese M, et al. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med 2018; 197(2): 214–24. PubMed PMC

Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med 2017; 377(21): 2024–35. PubMed PMC

Davies JC, Moskowitz SM, Brown C, et al. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 2018; 379(17): 1599–611. PubMed PMC

Keating D, Marigowda G, Burr L, et al. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 2018; 379(17): 1612–20. PubMed PMC

Molinski SV, Ahmadi S, Ip W, et al. Orkambi(R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. EMBO Mol Med 2017; 9(9): 1224–43. PubMed PMC

Mutyam V, Libby EF, Peng N, et al. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J Cyst Fibros 2017; 16(1): 24–9. PubMed PMC

Berkers G, van Mourik P, Vonk AM, et al. Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis. Cell Rep 2019; 26(7): 1701–8 e3. PubMed

Graeber SY, Dopfer C, Naehrlich L, et al. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Am J Respir Crit Care Med 2018; 197(11): 1433–42. PubMed

Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3(11): 1280–4. PubMed

Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2(4): 467–9. PubMed

Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349(15): 1433–41. PubMed

Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163(7): 1683–92. PubMed

Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 38(1): 59–69. PubMed

Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014; 2(7): 539–47. PubMed PMC

Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182(10): 1262–72. PubMed

Xue X, Mutyam V, Tang L, et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol 2014; 50(4): 805–16. PubMed PMC

Mutyam V, Du M, Xue X, et al. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations. Am J Respir Crit Care Med 2016; 194(9): 1092–103. PubMed PMC

Roy B, Friesen WJ, Tomizawa Y, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci U S A 2016; 113(44): 12508–13. PubMed PMC

Xue X, Mutyam V, Thakerar A, et al. Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences. Hum Mol Genet 2017; 26(16): 3116–29. PubMed PMC

van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357(26): 2677–86. PubMed

Anthony K, Arechavala-Gomeza V, Ricotti V, et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol 2014; 71(1): 32–40. PubMed

Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 2017; 377(18): 1723–32. PubMed

Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine. Front Pharmacol 2019; 10: 121. PubMed PMC

Montoro DT, Haber AL, Biton M, et al. A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 2018; 560(7718): 319–24. PubMed PMC

Cholon DM, Gentzsch M. Recent progress in translational cystic fibrosis research using precision medicine strategies. J Cyst Fibros 2018; 17(2S): S52–S60. PubMed PMC

Clancy JP, Cotton CU, Donaldson SH, et al. CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros 2019; 18(1): 22–34. PubMed PMC

Eckford PDW, McCormack J, Munsie L, et al. The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF. J Cyst Fibros 2019; 18(1): 35–43. PubMed

Gentzsch M, Boyles SE, Cheluvaraju C, et al. Pharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial Cells. Am J Respir Cell Mol Biol 2017; 56(5): 568–74. PubMed PMC

Veit G, Xu H, Dreano E, et al. Structure-guided combination therapy to potently improve the function of mutant CFTRs. Nat Med 2018; 24(11): 1732–42. PubMed PMC

Brewington JJ, Filbrandt ET, LaRosa FJ 3rd, et al. Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies. JCI Insight 2018; 3(13). PubMed PMC

Pranke I, Hatton A, Masson A, et al. Might Brushed Nasal Cells Be a Surrogate for CFTR Modulator Clinical Response? Am J Respir Crit Care Med 2019; 199(1): 123–6. PubMed

Wong AP, Bear CE, Chin S, et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol 2012; 30(9): 876–82. PubMed PMC

Dekkers JF, Wiegerinck CL, de Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19(7): 939–45. PubMed

van Mourik P, Beekman JM, van der Ent CK. Intestinal organoids to model Cystic Fibrosis. Eur Respir J 2019. PubMed

Guimbellot JS, Leach JM, Chaudhry IG, et al. Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight 2017; 2(22). PubMed PMC

Hirtz S, Gonska T, Seydewitz HH, et al. CFTR Cl-channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004; 127(4): 1085–95. PubMed

Masson A, Schneider-Futschik EK, Baatallah N, et al. Predictive factors for lumacaftor/ivacaftor clinical response. J Cyst Fibros 2018. PubMed

De Boeck K, Kent L, Davies J, et al. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 2013; 41(1): 203–16. PubMed

JC D. https://www.sciencedirect.com/science/article/pii/S1569199319301110?via%3Dihub. 2019.

De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 2014; 13(6): 674–80. PubMed

Giuliano KA, Wachi S, Drew L, et al. Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors. SLAS Discov 2018; 23(2): 111–21. PubMed PMC

Mayer-Hamblett N, Boyle M, VanDevanter D. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Thorax 2016; 71(5): 454–61. PubMed PMC

VanDevanter DR, Mayer-Hamblett N. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies. Curr Opin Pulm Med 2017; 23(6): 530–5. PubMed PMC

Goss CH, Bell SC. Aztreonam for inhalation solution, challenges to drug approval and integration into CF care. J Cyst Fibros 2013; 12(2): 99–101. PubMed

VanDevanter DR, Mayer-Hamblett N, Boyle M. Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation. J Cyst Fibros 2017; 16(4): 496–8. PubMed

https://www.ema.europa.eu/en/documents/report/report-workshop-patients-voice-evaluation-medicines_en.pdf.

Nichols DP, Durmowicz AG, Field A, Flume PA, VanDevanter DR, Mayer-Hamblett N. Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Ann Am Thorac Soc 2019; 16(5): 534–9. PubMed PMC

Perrem LRF. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators. Pediatr Pulmonol 2019; in press. PubMed

van Horck M, Winkens B, Wesseling G, et al. Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function. Sci Rep 2017; 7(1): 12350. PubMed PMC

Lechtzin N, Mayer-Hamblett N, West NE, et al. Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. Am J Respir Crit Care Med 2017; 196(9): 1144–51. PubMed PMC

Zwart TC, Gokoel SRM, van der Boog PJM, et al. Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. Br J Clin Pharmacol 2018; 84(12): 2889–902. PubMed PMC

Elliott TG, Dooley KC, Zhang M, Campbell HSD, Thompson DJS. Comparison of Glycated Hemoglobin Results Based on At-Home and In-Lab Dried Blood Spot Sampling to Routine Venous Blood Sampling In-Lab in Adult Patients With Type 1 or Type 2 Diabetes. Can J Diabetes 2018; 42(4): 426–32 e1. PubMed

Subbarao P, Stanojevic S, Brown M, et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 2013; 188(4): 456–60. PubMed PMC

Stahl M, Graeber SY, Joachim C, et al. Three-center feasibility of lung clearance index in infants and preschool children with cystic fibrosis and other lung diseases. J Cyst Fibros 2018; 17(2): 249–55. PubMed

Mott LS, Park J, Murray CP, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012; 67(6): 509–16. PubMed

Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368(21): 1963–70. PubMed

Wielputz MO, Puderbach M, Kopp-Schneider A, et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014; 189(8): 956–65. PubMed

Stahl M, Wielputz MO, Graeber SY, et al. Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis. Am J Respir Crit Care Med 2017; 195(3): 349–59. PubMed

Pennati F, Salito C, Borzani I, et al. Quantitative multivolume proton-magnetic resonance imaging in patients with cystic fibrosis lung disease: comparison with clinical indicators. Eur Respir J 2019; 53(5). PubMed

Wielputz MO, von Stackelberg O, Stahl M, et al. Multicentre standardisation of chest MRI as radiation-free outcome measure of lung disease in young children with cystic fibrosis. J Cyst Fibros 2018; 17(4): 518–27. PubMed

https://www.ema.europa.eu/en/documents/report/report-workshop-endpoints-cystic-fibrosis-clinical-trials_en.pdf.

Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J 2014; 44(4): 1042–54. PubMed

Dasenbrook EC, Sawicki GS. Cystic fibrosis patient registries: A valuable source for clinical research. J Cyst Fibros 2018; 17(4): 433–40. PubMed

Goss CH, Mayer-Hamblett N, Kronmal RA, Ramsey BW. The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases. Adv Drug Deliv Rev 2002; 54(11): 1505–28. PubMed

De Boeck K, Bulteel V, Tiddens H, et al. Guideline on the design and conduct of cystic fibrosis clinical trials: the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN). J Cyst Fibros 2011; 10 Suppl 2: S67–74. PubMed

https://www.ema.europa.eu/en/partners-networks/international-activities.

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf.

https://www.ema.europa.eu/en/documents/report/report-european-network-paediatric-research-european-medicines-agency-workshop-gastrointestinal-gi_en.pdf.

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr-cf-pharmaco_en.pdf.

https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance/parallel-consultation-regulators-health-technology-assessment-bodies.

Wise J. NHS and Vertex remain deadlocked over price of cystic fibrosis drug. BMJ 2019; 364: l1094. PubMed

McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361(9370): 1671–6. PubMed

Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006; 174(7): 787–94. PubMed PMC

Ronan NJ, Einarsson GG, Twomey M, et al. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor. Chest 2018; 153(2): 395–403. PubMed

Hisert KB, Heltshe SL, Pope C, et al. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Am J Respir Crit Care Med 2017; 195(12): 1617–28. PubMed PMC

Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med 2017; 5(2): 107–18. PubMed

Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180(2): 146–52. PubMed

Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med 2016; 4(8): 653–61. PubMed

Trimble AT, Donaldson SH. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 2018; 17(2): e13–e6. PubMed

Savitski MM, Reinhard FB, Franken H, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 2014; 346(6205): 1255784. PubMed

Hou Y, Guan X, Yang Z, Li C. Emerging role of cystic fibrosis transmembrane conductance regulator - an epithelial chloride channel in gastrointestinal cancers. World J Gastrointest Oncol 2016; 8(3): 282–8. PubMed PMC

Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71 Suppl 1: i1–22. PubMed PMC

Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science 2012; 335(6069): 645. PubMed

Jones AM, Barry PJ. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax 2015; 70(7): 615–6. PubMed

Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 2015; 19(14): 1–503, v–vi. PubMed PMC

Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Econ 2015; 24(1): 1–7. PubMed

Appleby J. Crossing the line: NICE’s value for money threshold. BMJ 2016; 352: i1336. PubMed

Collins M, Latimer N. NICE’s end of life decision making scheme: impact on population health. BMJ 2013; 346: f1363. PubMed

Paulden M. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable? Expert Rev Pharmacoecon Outcomes Res 2017; 17(3): 239–42. PubMed

Vernon JA, Goldberg R, Golec J. Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation. Pharmacoeconomics 2009; 27(10): 797–806. PubMed

Williams A. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ 1997; 6(2): 117–32. PubMed

Whiting P, Al M, Burgers L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess 2014; 18(18): 1–106. PubMed PMC

http://www.ncpe.ie/wp-content/uploads/2015/12/Ivacaftor-2-5-years-web-summary.pdf.

https://www.scottishmedicines.org.uk/medicines-advice/ivacaftor-kalydeco-fullsubmission-119316/

Schlander M, Garattini S, Holm S, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res 2014; 3(4): 399–422. PubMed

https://www.who.int/en/news-room/fact-sheets/detail/substandard-and-falsified-medical-products.

Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc 2011; 14: 15. PubMed PMC

Global Burden of Disease Health Financing Collaborator N. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. Lancet 2019; 393(10187): 2233–60. PubMed PMC

Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis 2014; 9: 62. PubMed PMC

Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 – 2020. Orphanet J Rare Dis 2011; 6: 62. PubMed PMC

Muther EF, Polineni D, Sawicki GS. Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. Pediatr Pulmonol 2018; 53(S3): S86–S92. PubMed

Abbott J, Havermans T, Jarvholm S, et al. Mental Health screening in cystic fibrosis centres across Europe. J Cyst Fibros 2019; 18(2): 299–303. PubMed

Havermans T, Tack J, Vertommen A, Proesmans M, de Boeck K. Breaking bad news, the diagnosis of cystic fibrosis in childhood. J Cyst Fibros 2015; 14(4): 540–6. PubMed

Simms R, Cole FS. The many roles of family members in “family-centered care”--part II. Interview by Deborah Dokken. Pediatr Nurs 2007; 33(1): 51–2, 70. PubMed

Tluczek A, Clark R, McKechnie AC, Brown RL. Factors affecting parent-child relationships one year after positive newborn screening for cystic fibrosis or congenital hypothyroidism. J Dev Behav Pediatr 2015; 36(1): 24–34. PubMed PMC

Anna Elderton KV, Trudy Havermans, Doris Staab. Understanding and working with challenging behaviours and fears in pre-school children with Cystic Fibrosis. ECFS publication 2018; The early Cystic Fibrosis Years.

Jamieson N, Fitzgerald D, Singh-Grewal D, Hanson CS, Craig JC, Tong A. Children’s experiences of cystic fibrosis: a systematic review of qualitative studies. Pediatrics 2014; 133(6): e1683–97. PubMed

Coyne I, Sheehan AM, Heery E, While AE. Improving transition to adult healthcare for young people with cystic fibrosis: A systematic review. J Child Health Care 2017; 21(3): 312–30. PubMed

Haarbauer-Krupa J, Alexander NM, Mee L, et al. Readiness for transition and health-care satisfaction in adolescents with complex medical conditions. Child Care Health Dev 2019; 45(3): 463–71. PubMed

Barker H, Moses J, O’Leary C. ‘I’ve got to prioritise’: being a parent with cystic fibrosis. Psychol Health Med 2017; 22(6): 744–52. PubMed

Nick JA, Nichols DP. Diagnosis of Adult Patients with Cystic Fibrosis. Clin Chest Med 2016; 37(1): 47–57. PubMed

Sawicki GS, Sellers DE, McGuffie K, Robinson W. Adults with cystic fibrosis report important and unmet needs for disease information. J Cyst Fibros 2007; 6(6): 411–6. PubMed

Braithwaite M, Philip J, Tranberg H, et al. End of life care in CF: patients, families and staff experiences and unmet needs. J Cyst Fibros 2011; 10(4): 253–7. PubMed

Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax 2014; 69(12): 1090–7. PubMed

Butcher JL, Nasr SZ. Direct observation of respiratory treatments in cystic fibrosis: parent-child interactions relate to medical regimen adherence. J Pediatr Psychol 2015; 40(1): 8–17. PubMed

Goldbeck L, Fidika A, Herle M, Quittner AL. Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database Syst Rev 2014; (6): CD003148. PubMed PMC

Quittner AL, Abbott J, Georgiopoulos AM, et al. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax 2016; 71(1): 26–34. PubMed PMC

Narayanan S, Mainz JG, Gala S, Tabori H, Grossoehme D. Adherence to therapies in cystic fibrosis: a targeted literature review. Expert Rev Respir Med 2017; 11(2): 129–45. PubMed

Faint NR, Staton JM, Stick SM, Foster JM, Schultz A. Investigating self-efficacy, disease knowledge and adherence to treatment in adolescents with cystic fibrosis. J Paediatr Child Health 2017; 53(5): 488–93. PubMed

Oates GR, Stepanikova I, Rowe SM, Gamble S, Gutierrez HH, Harris WT. Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis. Respir Care 2019; 64(2): 176–81. PubMed PMC

Velez-Velez E, Bosch RJ. Illness perception, coping and adherence to treatment among patients with chronic kidney disease. J Adv Nurs 2016; 72(4): 849–63. PubMed

Pakhale S, Baron J, Armstrong M, et al. Lost in translation? How adults living with Cystic Fibrosis understand treatment recommendations from their healthcare providers, and the impact on adherence to therapy. Patient Educ Couns 2016; 99(8): 1319–24. PubMed

Shakkottai A, Kidwell KM, Townsend M, Nasr SZ. A five-year retrospective analysis of adherence in cystic fibrosis. Pediatr Pulmonol 2015; 50(12): 1224–9. PubMed

Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006; 5(3): 177–85. PubMed

Bucks RS, Hawkins K, Skinner TC, Horn S, Seddon P, Horne R. Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs. J Pediatr Psychol 2009; 34(8): 893–902. PubMed

Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006; 38(1): 13–7. PubMed

Goodfellow NA, Hawwa AF, Reid AJ, Horne R, Shields MD, McElnay JC. Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms. BMC Pulm Med 2015; 15: 43. PubMed PMC

Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol 2012; 47(6): 523–33. PubMed

Flewelling KD, Sellers DE, Sawicki GS, Robinson WM, Dill EJ. Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. J Cyst Fibros 2019. PubMed

Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros 2019. PubMed

Nakagawa S. Communication--The Most Challenging Procedure. JAMA Intern Med 2015; 175(8): 1268–9. PubMed

Nakagawa S. Communicating With Patients--The Other Side of the Conversation--Reply. JAMA Intern Med 2015; 175(12): 1997. PubMed

Takaki H, Abe T, Hagihara A. Physicians’ and pharmacists’ information provision and patients’ psychological distress. J Interprof Care 2017; 31(5): 575–82. PubMed

Transition to adult care, Ready Steady, Go. www.uhs.nhs.uk/OurServices/Childhealth/TransitiontoadultcareReadySteadyGo/Transitiontoadultcare.aspx

Cystic Fibrosis Trust: Factsheets, information packs and publications.

Age-Specific Care Guidelines.

Ketchell RI. Telemedicine is the way forward for the management of cystic fibrosis - the case in favour. Paediatr Respir Rev 2018; 26: 19–21. PubMed

Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol 2007; 2(2): 153–64. PubMed

Kidd TJ, Soares Magalhaes RJ, Paynter S, Bell SC, Group ACI. The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis. Lancet Respir Med 2015; 3(8): 640–50. PubMed

Cox NS, Alison JA, Rasekaba T, Holland AE. Telehealth in cystic fibrosis: a systematic review. J Telemed Telecare 2012; 18(2): 72–8. PubMed

Hardisty AR, Peirce SC, Preece A, et al. Bridging two translation gaps: a new informatics research agenda for telemonitoring of chronic disease. Int J Med Inform 2011; 80(10): 734–44. PubMed

Sarfaraz S, Sund Z, Jarad N. Real-time, once-daily monitoring of symptoms and FEV in cystic fibrosis patients--a feasibility study using a novel device. Clin Respir J 2010; 4(2): 74–82. PubMed

Chen JJ, Cooper DM, Haddad F, Sladkey A, Nussbaum E, Radom-Aizik S. Tele-Exercise as a Promising Tool to Promote Exercise in Children With Cystic Fibrosis. Front Public Health 2018; 6: 269. PubMed PMC

Garner SL, Sudia T, Rachaprolu S. Smart phone accessibility and mHealth use in a limited resource setting. Int J Nurs Pract 2018; 24(1). PubMed

Van Allen J, Davis AM, Lassen S. The use of telemedicine in pediatric psychology: research review and current applications. Child Adolesc Psychiatr Clin N Am 2011; 20(1): 55–66. PubMed PMC

Coleman MT, Newton KS. Supporting self-management in patients with chronic illness. Am Fam Physician 2005; 72(8): 1503–10. PubMed

Polonsky WH, Fisher L, Hessler D, Edelman SV. What is so tough about self-monitoring of blood glucose? Perceived obstacles among patients with Type 2 diabetes. Diabet Med 2014; 31(1): 40–6. PubMed

Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011; 140(2): 425–32. PubMed

Roehrer E, Cummings E, Beggs S, et al. Pilot evaluation of web enabled symptom monitoring in cystic fibrosis. Inform Health Soc Care 2013; 38(4): 354–65. PubMed

Roehrer E, Cummings E, Turner P, et al. Supporting cystic fibrosis with ICT. Stud Health Technol Inform 2013; 183: 137–41. PubMed

Community unites to call for #OrkambiNow!

Stephenson AL, Sykes J, Stanojevic S, et al. Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study. Ann Intern Med 2017; 166(8): 537–46. PubMed PMC

Keogh RH, Bilton D, Cosgriff R, Kavanagh D, Rayner O, Sedgwick PM. Results from an online survey of adults with cystic fibrosis: Accessing and using life expectancy information. PLoS One 2019; 14(4): e0213639. PubMed PMC

https://www.cysticfibrosis.org.uk/news/darzi-fellowship-brings-new-insights-into-registry-development. https://www.cysticfibrosis.org.uk/news/darzi-fellowship-brings-new-insights-into-registry-development.

The relationship between cancer risk and cystic fibrosis: the role of CFTR in cell growth and cancer development

Analyses of 1236 genotyped primary ciliary dyskinesia individuals identify regional clusters of distinct DNA variants and significant genotype-phenotype correlations

Building global development strategies for cf therapeutics during a transitional cftr modulator era